pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,633 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1084Endpoints820BioPharma Dive315BioSpace251Fierce Biotech236onclive165raps90globenewswire health
therapy area
allOncology6572Rare Disease1540Cardiology1254Immunology1169Hematology1115Vaccines1013Pulmonology
  • Pfizer CFO Dave Denton to leave; Denali Therapeutics sells $195 million FDA priority review voucher
    Pfizer announced that its chief financial officer Dave Denton will depart on Aug. 15 to take a role outside the pharmaceutical sector. He has been CFO since May 2022. In the interim, finance chief…
    BioPharma Dive · 2mo agoDealNeutral↗ source
  • Pfizer CFO to leave in August as GSK secures approval for urinary-tract infection drug
    Pfizer announced that its chief financial officer, Dave Denton, will step down in August, ending his tenure at the company. GSK reported that it has received regulatory approval for a new treatmen…
    Endpoints · 2mo agoRegulatoryNeutral↗ source
← prev
page 65 of 106
next →
73
fda recalls56
fda medwatch50
fda press32
965
Psychiatry & CNS769
Ophthalmology461
Pain428
Endocrinology & Metabolism404
Infectious Disease384
  • Shingles vaccine linked to 24% lower dementia risk in nursing home residents, study shows
    A new study of elderly nursing home residents examined the effect of receiving at least one dose of the shingles vaccine Shingrix on dementia incidence over a four year period. The analysis found…
    STAT · 2mo agoPositive readoutPositive↗ source
  • Biogen to acquire RayThera for up to $1 billion as J&J shifts focus away from obesity to cancer
    Biogen announced an agreement to purchase RayThera for as much as $1 billion, marking the company's second takeover this year. The deal expands Biogen's portfolio into RayThera's pipeline, though s…
    STAT · 2mo agoDealNeutral↗ source
  • Novocure's electric field therapy fails Phase 3 glioblastoma trial, not extending patient survival
    Novocure announced on Thursday that its electric fields device, used together with standard chemoradiation, did not improve overall survival for patients with glioblastoma in a Phase 3 trial. The…
    Endpoints · 2mo agoNegative readoutNegative↗ source
  • New poll shows only half of U.S. adults can afford quality health care, with record-high concerns for next year
    A recent West Health-Gallup Affordability Index found that roughly 50% of American adults said they could pay for health care and still access quality services in the past year. The survey also re…
    STAT · 2mo agoNegative↗ source
  • Moderna appoints Ester Banque as chief commercial officer and expands Stephen Hoge's responsibilities
    Moderna announced a leadership reshuffle as it readies for upcoming product launches. The company named Ester Banque, who previously led U.S. operations at animal health firm Zoetis, as its new ch…
    Endpoints · 2mo agoNeutral↗ source
  • Eli Lilly's TuneLab AI platform reaches 100 members and integrates Chai's models
    Eli Lilly has built TuneLab, an AI initiative that gives biotech companies free access to a range of artificial‑intelligence tools to support drug discovery and development. The program recently a…
    Endpoints · 2mo agoPositive↗ source
  • Super-potent nitazene opioids linked to sharp rise in U.S. overdose deaths
    Synthetic opioids known as nitazenes, which can be up to forty times stronger than fentanyl, are increasingly being found mixed into other street drugs across the United States. The Centers for Di…
    STAT · 2mo agoNegative↗ source
  • Eli Lilly stops 340B discounts for dozens of hospitals that did not submit claims data
    Eli Lilly has begun removing the federally mandated 340B price discounts for a few dozen hospitals that have not provided the required claims data. The company said the step follows a warning it is…
    STAT · 2mo agoRegulatoryNegative↗ source
  • RA Capital, Forbion and Sanofi Ventures back Korean eye-drug startup
    RA Capital, Forbion and Sanofi Ventures are reported to be providing financing for a new eye-drug company that is developing its product in Korea. The investment follows a growing pattern where la…
    Endpoints · 2mo agoDealNeutral↗ source
  • Former Senators Urge Congress to Prioritize Global Health as Strategic Diplomacy
    The authors, former U.S. senators, argue that improving global health must become a top priority for the United States, especially in light of recent outbreaks such as hantavirus and Ebola, which l…
    STAT · 2mo agoPositive↗ source
  • Patrick Soon-Shiong's pancreatic cancer claims lag behind reality, STAT reports
    STAT's Adam Feuerstein notes a wide gap between the outcomes promised by Patrick Soon-Shiong's pancreatic cancer therapies and the results that have actually been delivered. The columnist highlight…
    STAT · 2mo agoNegative↗ source
  • AI's rising electricity and water demand poses a public health risk, authors warn
    Two public-health scholars argue that the expanding use of artificial intelligence is creating a hidden strain on essential services such as electricity and water. They note that the massive data c…
    STAT · 2mo agoNegative↗ source
  • STAT Health Tech examines whether wearables benefit cardiovascular patients
    Mario Aguilar writes in a STAT Health Tech newsletter that the issue of wearables for people with cardiovascular disease is under review. The piece notes that researchers have been studying whether…
    STAT · 2mo agoNeutral↗ source
  • Cambrian’s experimental longevity drug shown to mimic exercise effects
    Cambrian Therapeutics reported early data on a new compound aimed at extending healthy lifespan by reproducing some benefits of physical activity. The preclinical studies described in the newslett…
    STAT · 2mo agoNeutral↗ source
  • Innoviva revives Lyndra's long-acting oral drug platform
    Innoviva, a healthcare asset and royalties holding firm, announced it is bringing back Lyndra's long-acting oral drug delivery platform. The technology, which previously attracted more than $380 mi…
    Endpoints · 2mo agoPositive↗ source
  • Industry eyes revenue potential of next‑generation peptide drugs beyond GLP‑1
    The article notes that just a few years ago analysts were busy estimating the market size for GLP‑1 based weight‑loss medicines. Today the conversation has shifted toward the commercial possibilit…
    Endpoints · 2mo agoNeutral↗ source
  • Trump administration earmarks $700 million for mental health and addiction programs, experts say funds are existing grants
    The Trump administration announced a $700 million allocation for mental health and addiction initiatives. Health Secretary Robert F. Kennedy Jr. described the money as new investments, but behavio…
    STAT · 2mo agoRegulatoryNeutral↗ source
  • STAT+: Senate Democrats demand HHS provide records on federal vaccine policy
    Senate Democrats open an inquiry into the Trump administration’s remaking of U.S. vaccine policy, demanding officials produce records by next week.
    STAT · 2mo ago↗ source
  • What’s next for GLP-1 weight loss drugs?
    What’s next for GLP-1 weight loss drugs? Alex Hogan explores on the new episode of STATus Report. Watch now.
    STAT · 2mo ago↗ source
  • Antifungal from F2G, Shionogi succeeds in Phase 3 study
    F2G and Shionogi released positive Phase 3 data on Thursday morning, giving the companies a potentially clear path to approval for their antifungal drug. The companies said their treatment called o…
    Endpoints · 2mo ago↗ source
  • Kardigan extends biotech’s streak of big IPOs with $400M haul
    Including the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to BioPharma Dive data.
    BioPharma Dive · 2mo ago↗ source
  • Kardigan raises $400M in IPO to back three clinical-stage cardio drugs
    More evidence has arrived that biotech IPOs are alive and well: A cardiology drug developer with three clinical-stage candidates just secured $400 million for its Nasdaq debut slated for Thursday.…
    Endpoints · 2mo ago↗ source
  • Biogen makes up to $1B deal for secretive anti-inflammatory biotech
    Biogen will pay as much as $1 billion — “predominantly” in milestone payments — to acquire a San Diego biotech that has disclosed little about its pipeline. The startup, RayThera, debuted last year…
    Endpoints · 2mo ago↗ source